Increased presence of CD4+ T cells is correlated with better survival in cancer patients [32,33], while a higher CD4-to-CD8 ratio of T cells in leukapheresis products used for making CAR T therapies has been shown to improve anti-tumor responses with better clinical outcomes [30,34,35]. The gene discussed is CD4; the disease is cancer.